Michelle Carr, Author at BioTuesdays

Markets

Jefferies starts Profound Medical at buy; PT $31 (Canadian)

Jefferies launched coverage of Profound Medical (TSX:PRN; NASDAQ:PROF) with a “buy” rating and price target of $31 (Canadian). The stock closed at $18.69 on Sept. 14. Analyst Raj Denhoy writes that Profound’s TULSA-PRO...

September 15, 2020

Markets

AGP ups Motus GI Holdings PT to $2.60 from $1.65

Alliance Global Partners raised its price target for Motus GI Holdings (NASDAQ:MOTS) to $2.60 from $1.65, “rolling our valuation multiple onto our newly introduced 2022 estimates and utilizing 50 million as our share...

September 9, 2020

Markets

Cowen starts Alphatec Spine at OP; PT $12

Cowen launched coverage of Alphatec Spine (NASDAQ:ATEC) with an “outperform” rating and $12 price target. The stock closed at $6.09 on Sept. 2. Alphatec designs, develops, manufactures and markets surgical spine...

September 3, 2020

Markets

Echelon cuts Acasti Pharma to sell; PT to 15 cents

Echelon Wealth Partners downgraded Acasti Pharma (TSXV:ACST) to “sell” from “speculative buy” and slashed its price target to 15 cents (Canadian) from $1.40 after the company reported that its Phase 3 TRILOGY 2 trial...

September 1, 2020

Developments

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

iBio (NYSE AMERICAN:IBIO) entered into an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc. ACE2-Fc is a recombinant protein...

August 28, 2020

Developments

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

CohBar (NASDAQ:CWBR) dosed first subjects with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for non-alcoholic steatohepatitis (NASH) and obesity. The Phase 1b study is designed to evaluate one dose...

August 24, 2020

Markets

SVB Leerink starts iTeos Therapeutics at OP; PT $36

SVB Leerink launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with an “outperform” rating and $36 price target. The stock closed at $32.92 on Aug. 18. “Though the stock has rallied since the IPO, we see potential...

August 18, 2020

Markets

Maxim ups Heat Biologics PT to $5 from $2

Maxim Group raised its price target for Heat Biologics (NASDAQ:HTBX) to $5 from $2, citing the potential of the company’s vaccine platform to produce long-lasting cellular immunity against COVID-19. The stock closed at...

July 27, 2020

Executive Moves

Canaccord boosts healthcare investment banking team

Canaccord Genuity named Thomas O’Connor as managing director, co-head of U.S. healthcare investment banking, with long-time partners, Matt Steere and Eugene Rozelman, joining Mr. O’Connor as fellow co-heads of the U.S...

July 23, 2020

Developments

IntelGenx and Tilray amend exclusivity of cannabis-infused VersaFilm accord

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Tilray (NASDAQ:TLRY) amended the exclusivity terms of their November 2018 license, development and supply agreement to allow for IntelGenx’s co-development and commercialization of...

July 20, 2020

Author - Michelle Carr

Jefferies starts Profound Medical at buy; PT $31 (Canadian)

AGP ups Motus GI Holdings PT to $2.60 from $1.65

Cowen starts Alphatec Spine at OP; PT $12

Echelon cuts Acasti Pharma to sell; PT to 15 cents

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

SVB Leerink starts iTeos Therapeutics at OP; PT $36

Maxim ups Heat Biologics PT to $5 from $2

Canaccord boosts healthcare investment banking team

IntelGenx and Tilray amend exclusivity of cannabis-infused VersaFilm accord

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter